- Ivermectin is proven to treat a variety of different cancers.
- Lung cancer is one of them.
In a previous article titled How Ivermectin Is Useful for Treating Cancer we covered the evidence for the benefits of Ivermectin for cancer. But the question of which cancers Ivermectin has been proven to be effective is a constant source of questions.
This article provides an overview coverage of these specific cancers.
There are a lot of quotes in this article, but I have a short one for each cancer type. The article uses the term “IVM” to mean Ivermectin.
Cancer Type #1: Lung Cancer
Here is the finding of the study Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth.
Lung cancer has the highest morbidity and mortality among cancers . Nishio found that IVM could significantly inhibit the proliferation of H1299 lung cancer cells by inhibiting YAP1 activity . Nappi’s experiment also proved that IVM combined with erlotinib to achieved a synergistic killing effect by regulating EGFR activity and in HCC827 lung cancer cells . In addition, IVM could reduce the metastasis of lung cancer cells by inhibiting EMT.
In a study that screened drugs for the treatment of nasopharyngeal cancer, IVM significantly inhibited the development of nasopharyngeal carcinoma in nude mice at doses that were not toxic to normal thymocytes. – NIH
This study was funded by science foundations out of China.
The Importance of The NIH Stopping Any Funding For Ivermectin Studies
Notice that none of the studies on Ivermectin were performed in the US. The US has by far the largest national medical research budget in the world, and so if the US is not performing studies, this is not only a negative but tells us something peculiar about what the NIH is deciding not to fund in the area of cancer research.
Zero is the number of studies funded by the NIH on Ivermectin. The NIH will not fund studies into generic drugs, as the NIH is controlled by pharmaceutical companies and they have deep financial ties to them. Funding research into generic drugs could end up showing those drugs as effective, which is a threat to pharmaceutical profits, which the NIH is dedicated to maximizing.
Interested in More?
Would you like to get access to 100% independent medical information?
Regarding dosage and sourcing of Ivermectin, see the article On the Topic of Ivermectin Dosage and Sourcing.
Why Are Anti Parasitic Drugs Effective Against Cancer?
If you want to understand why this class of drugs works against cancer, see the article The Mechanism of How Anti Parasitic Drugs Work to Mitigate Cancer.
Testing Evidence for Ivermectin
The following quotes are from the article Ivermectin, a potential anticancer drug derived from an antiparasitic drug.
Impact #1: Inhibiting Proliferation of Tumor Cells
Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways.
The Ivermectin blocking of PAK1 proteins, aka activated kinase, is a reason for this.
The instrumentality of PAK1 in cancer growth is explained in the following quotation from the article Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations.
In human lung cancer and NF2 tumor cell lines, high-dose ivermectin inactivates protein kinase PAK1 and blocks PAK1-dependent growth.
PAK proteins are essential for cytoskeletal reorganization and nuclear signaling, PAK1 being implicated in tumor genesis while inhibiting PAK1 signals induces tumor cell apoptosis (cell death).
PAK1 becomes hyperactive in cancer cells for reasons that are not yet understood.
Ivermectin can be viewed as a PAK1 restrictor or modulator (I say modulator as PAK1 is present in normal healthy cells, but an overage of PAK is a prime cause of cancer. This means that Ivermectin interferes with a precursor to cancer. This modulating influence on PAK is another reason Ivermectin is effective against many types of cancer.
PAK1 is implicated in multiple cancers if found in the quotation from the article Effect of P21-activated kinase 1 (PAK-1) inhibition on cancer cell growth, migration, and invasion.